Drug Profile
Research programme: autoimmune disease therapeutics - Atox Bio
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Atox Bio
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel (SC)
- 30 Jun 2009 Preclinical trials in Autoimmune disorders in Israel (SC)